Canaccord Genuity restated their buy rating on shares of Genomic Health (NASDAQ:GHDX) in a research report sent to investors on Wednesday morning, The Fly reports. The brokerage currently has a $82.00 price objective on the medical research company’s stock, up from their previous price objective of $70.00.

Other research analysts have also recently issued research reports about the stock. Piper Jaffray Companies reissued a hold rating and set a $60.00 price target on shares of Genomic Health in a research report on Friday, August 3rd. Cowen reissued a hold rating and set a $50.00 price target on shares of Genomic Health in a research report on Monday, August 6th. Zacks Investment Research cut shares of Genomic Health from a strong-buy rating to a hold rating in a research report on Tuesday, July 24th. BidaskClub cut shares of Genomic Health from a strong-buy rating to a buy rating in a research report on Thursday, October 4th. Finally, Jefferies Financial Group reissued a hold rating and set a $50.00 price target on shares of Genomic Health in a research report on Friday, August 3rd. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating, two have issued a buy rating and two have issued a strong buy rating to the stock. The company presently has an average rating of Hold and a consensus target price of $48.33.

Shares of Genomic Health stock traded down $2.11 during trading hours on Wednesday, reaching $81.67. 1,054,132 shares of the company’s stock were exchanged, compared to its average volume of 332,033. Genomic Health has a 1 year low of $26.54 and a 1 year high of $92.18. The firm has a market capitalization of $3.23 billion, a price-to-earnings ratio of 8,167.00 and a beta of 0.44.

Genomic Health (NASDAQ:GHDX) last announced its quarterly earnings results on Tuesday, November 6th. The medical research company reported $0.35 earnings per share for the quarter, beating the consensus estimate of $0.07 by $0.28. The firm had revenue of $101.30 million for the quarter, compared to analysts’ expectations of $94.27 million. Genomic Health had a net margin of 4.95% and a return on equity of 14.76%. The company’s revenue was up 23.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.06) EPS. As a group, equities analysts expect that Genomic Health will post 1.06 EPS for the current fiscal year.

In other news, Director Fred E. Cohen sold 8,250 shares of the stock in a transaction that occurred on Thursday, September 6th. The stock was sold at an average price of $61.51, for a total value of $507,457.50. Following the completion of the sale, the director now directly owns 75,572 shares of the company’s stock, valued at $4,648,433.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Kimberly J. Popovits sold 60,000 shares of the stock in a transaction that occurred on Tuesday, August 14th. The shares were sold at an average price of $52.60, for a total value of $3,156,000.00. The disclosure for this sale can be found here. Insiders sold 228,750 shares of company stock worth $14,991,963 over the last quarter. 45.80% of the stock is currently owned by insiders.

Several hedge funds have recently bought and sold shares of GHDX. Globeflex Capital L P acquired a new stake in shares of Genomic Health in the second quarter valued at approximately $116,000. Sun Life Financial INC acquired a new stake in shares of Genomic Health in the second quarter valued at approximately $122,000. SG Americas Securities LLC acquired a new stake in shares of Genomic Health in the second quarter valued at approximately $162,000. Trexquant Investment LP acquired a new stake in shares of Genomic Health in the third quarter valued at approximately $202,000. Finally, Teacher Retirement System of Texas acquired a new stake in shares of Genomic Health in the second quarter valued at approximately $213,000. 89.90% of the stock is owned by institutional investors and hedge funds.

Genomic Health Company Profile

Genomic Health, Inc, a healthcare company, provides actionable genomic information to personalize cancer treatment decisions worldwide. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions.

Featured Story: Capital Gains

The Fly

Analyst Recommendations for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.